Credo Technology Group에 대한 매도 수량은 투자자에게 Credo Technology Group의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Credo Technology Group (NASDAQ:CRDO) 주식, 공매도 수량 보고

Credo Technology Group

Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.

Large Cap

News

Movers

Trading Ideas

CRDO

DOCU

LULU

MRVL

PSTG

RBRK

ROKU

SMCI

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 크레도 테크놀로지 그룹 홀딩(NASDAQ:CRDO) 주식은 2분기 실적 발표 후 주가가 51.61% 급등하였으며, 여러 회사들이 주식에 대한 가격 예측을 상향 조정했다.

슈퍼 마이크로, 룰루레몬 및 로쿠 지난주 최고 성과를 보여준 11개 대형주 중 일부 (12월 2일-6일)

크레도 테크놀로지 그룹 홀딩스(NASDAQ:CRDO)의 주가는 월요일에 예상치를 크게 상회하는 2025회계연도 2분기 재무 실적을 발표한 후 화요일(3일) 급등하고 있다. 알아 두어야 할 내용은 다음과 같다.

크레도 테크놀로지 주가 48% 급등, 무슨 일일까?

Earnings

Pre-Market Outlook

Markets

IMPP

XPEV

월요일(2일) 아침 미국 주식 선물이 하락세를 보이는 가운데 오늘 투자자들이 주목할 만한 종목은 다음과 같다. 임페리얼 페트롤리엄, 지스케일러, 니오, 샤오펑 및 크레도

월요일 주목해야 할 주식: 임페리얼 페트롤리엄, 지스케일러, 니오, 샤오펑 및 크레도

Credo Technology Group Holding Ltd - Ordinary Shares

Credo Technology Group Holding Ltd

Cerrado Gold Inc

Wedbush analyst Laura Chico reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Outperform and maintains $148 price target.

Price Target

Reiteration

Analyst Ratings

NBIX

Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $148 Price Target

Elon Musk is reportedly facing internal discussions about the risks of pursuing a higher security clearance for sensitive programs of SpaceX despite being the CEO. Concerns have been raised about potential government inquiries into Musk&#8217;s interactions with foreign nationals and past drug use.
What Happened: SpaceX&#8217;s legal team advised against Musk seeking a higher security clearance. The team feared that Musk might inadvertently reveal sensitive information during government questioning. This issue emerged as SpaceX&#8217;s involvement with national security agencies intensified. Although Musk holds a top-secret clearance, it does not grant access to certain classified programs, The Wall Street Journal <a href="https://www.wsj.com/tech/musk-spacex-security-clearance-secrets-b9774346">reported</a> on Monday.
According to the publication, Musk&#8217;s frequent communications with Russian President Vladimir Putin since late 2022 and his public drug use, including marijuana on a 2018 podcast, as factors in the extended review of his security clearance application. SpaceX&#8217;s legal team worried that pursuing a higher clearance could lead to Musk being denied or losing his existing clearance.
See Also:&nbsp;<a href="https://www.benzinga.com/24/12/42495770/trump-transition-team-advocates-for-abolishing-car-crash-reporting-rule-tesla-stands-to-gain?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Transition Team Advocates For Abolishing Car-Crash Reporting Rule, Tesla Stands To Gain: Report</a>
As President-elect Donald Trump announced Musk to lead the Department of Government Efficiency, there is potential for Musk to gain broader access to classified information. However, Trump has not yet publicly indicated whether he will grant such access. SpaceX is already preparing for the possibility by scouting secure facilities for Musk and his team.
Why It Matters: The potential appointment of Musk to the Department of Government Efficiency, also known as DOGE, has sparked controversy.&nbsp;Robert Reich, a former Clinton-era official, <a href="https://www.benzinga.com/politics/24/11/41962372/trumps-doge-with-musk-at-the-helm-riddled-with-conflicts-of-interest-says-clinton-era-official-robert-reich">criticized the move</a>, suggesting it could be riddled with conflicts of interest. Reich questioned the intentions behind forming this task force, implying it might not truly focus on efficiency.
Additionally, Musk&#8217;s views on drug use have drawn attention. In May, he humorously <a href="https://www.benzinga.com/news/24/05/38907748/days-after-facing-lawsuit-for-drug-use-musk-says-he-would-take-cocaine-if-it-boosted-long-term-produ">commented on&nbsp;X&nbsp;</a>about taking cocaine if it boosted productivity, following a lawsuit related to drug use. These factors contribute to the ongoing scrutiny surrounding Musk&#8217;s security clearance and potential government role.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/startups/24/12/42484881/musk-and-ramaswamy-may-target-this-surprising-government-role-that-pays-more-than-youd-think?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Musk and Ramaswamy May Target This Surprising Government Role That Pays More Than You&#8217;d Think</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Media

General

Elon Musk Doesn't Have Clearance For Certain SpaceX Programs Despite Being CEO: Report

BMO Capital analyst Bhavesh Lodaya maintains Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) with a Outperform and raises the price target from $32 to $34.

BMO Capital Maintains Outperform on Element Solutions, Raises Price Target to $34

Diana Shipping Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSX#NYSE">DSX</a>), (the "Company"), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with China Resource Chartering Limited, for one of its Panamax dry bulk vessels, the m/v Maera. The gross charter rate is US$8,400 per day, minus a 5.00% commission paid to third parties, for a period until minimum September 20, 2025 up to maximum November 20, 2025. The charter commenced on December 15, 2024.
The "Maera" is a 75,403 dwt Kamsarmax dry bulk vessel built in 2013.
The employment of "Maera" is anticipated to generate approximately US$2.31 million of gross revenue for the minimum scheduled period of the time charter.

Contracts

Diana Shipping Announces Time Charter Contract For m/v Maera; Gross Charter Rate Is $8,400 Per Day; Employment Of "Maera" Is Anticipated To Generate ~$2.31M Of Gross Revenue For The Minimum Scheduled Period Of The Time Charter

WIIM

AKTS

Akoustis Technologies shares are trading lower after the company announced it filed for Chapter 11 and is initiating the strategic sale of the business amid the Qorvo legal dispute.

JANA Partners ("JANA," "we" or "us") together with our strategic and operating partners beneficially own more than 5% of the outstanding shares of Lamb Weston Holdings, Inc. ("Lamb Weston" or the "Company"), making us one of the Company's largest shareholders. Having received no response from the Board to our months-long involvement and engagement, we are hopeful that the Company will use the upcoming fiscal second quarter earnings announcement to address our previously expressed view that significant Board and leadership change is needed at Lamb Weston, and that in its absence the Company should pursue a formal review of strategic alternatives, including a sale.
We believe Lamb Weston's Board and management have wasted the chance to sustain and grow shareholder value in a high-quality business. It is indisputable that Lamb Weston's track record for shareholders prior to the disclosure of our investment has been poor, not only in a disastrous 2024 (which includes an earnings report so ignominious that it prompted one long-tenured analyst to declare it "one of the worst days for a larger-cap food producer in modern history"),1 but also over the long-term with total returns in the last five years2 dramatically trailing the S&amp;P 500 and performing in the bottom quartile when compared to proxy peers.
Regrettably, we believe this dismal performance record significantly understates the magnitude of lost opportunity at the Company. Relative to its publicly traded packaged food peers, we believe Lamb Weston enjoys the benefits of an attractive end market, a strong industry position and key competitive advantages (including geographic ones). When coupled with Lamb Weston's long-time reputation as a premier foodservice supplier – which took prior management many years to build – we think these attributes should have positioned the Company as an attractive ‘compounder' stock and best-in-class performer for investors.
Instead, the current Board and management have overseen a multi-year period of uncorrelated failures across many major elements of operating the business, in the process damaging the Company's reputation and leading market position. This has impaired performance, dissolved confidence among customers, investors and other stakeholders and caused Lamb Weston to veer off its path as a world-class business.3
The disclosure of our involvement on October 18th led to an approximately $1 billion increase in Lamb Weston's market cap and an overwhelmingly positive reception from investors and Wall Street analysts,4 which we believe demonstrates the intense appetite from shareholders for a change in direction. The extensive investor feedback we have received since emerging publicly in the Company, including proprietary survey work that has included dozens of investors and other stakeholders, has further confirmed what was clear from our initial due diligence: that there is urgent need – and strong desire – for significant Board and leadership change at Lamb Weston.5
A failure of Board oversight has permitted chronic mis-execution, a bloated expense structure, poor capital allocation and questionable use and disclosure practices involving the Company's aviation assets. Making matters worse, the Board has supported management as Company leadership has attempted to place primary blame for the Company's challenges on end market softness – rather than offering a long overdue mea culpa and acknowledging the magnitude of damage inflicted on the business and investors from its litany of self-inflicted missteps.6 This contradicts what we believe to be an environment where the Company's primary competitors (all private companies) have enjoyed stronger performance at Lamb Weston's expense. This disconnect has not been lost on the investors and other stakeholders we have spoken with or who took part in a proprietary survey.7
Lamb Weston's failures include:
<ul>
<li>Significant Financial and Operating Deficiencies: These have cost the Company (at a minimum) nearly $400m8 in EBITDA over the past ~2.5 years and have eroded Lamb Weston's credibility with stakeholders across the value chain, from growers to customers.
<ul>
<li>A fumbled attempt to enhance its customer base by voluntarily ceasing business with some customers (i.e. ‘firing' them) before the Company had secured the superior replacement volume, resulting in lost market share and a volume shortfall that has weighed on revenue.</li>
<li>Mis-forecasting customer demand so dramatically that the Company has been forced to write off an inordinate amount of raw potatoes in both F2024 and F2025.9</li>
<li>Executing a multi-hundred million dollar ERP project riddled with delays (underway for almost a decade and now paused) where implementation failed so spectacularly that it left important Lamb Weston customers without products for a period in F3Q24, costing the Company both customers and reputational damage.</li>
<li>Failing to identify and address product quality problems for a key customer until so late in the process that the Company incurred ~$80m in losses from product withdrawal.</li>
<li>Generating little to no overhead cost leverage in the business despite doubling revenue over the last eight years,10 with the Company increasing its SG&amp;A targets from 8-8.5% sales to 10.5-11% in 2023.11</li>
</ul>
</li>
<li>Failed Oversight of Capital Allocation: The multi-year escalation of capital deployment – rubber-stamped by the Board and paired with misaligned incentives – led to elevated capex without acceptable returns, left the Company with no margin of safety when operational missteps surfaced, dramatically reduced free cash flow generation and eroded investor confidence in the Company. This includes:
<ul>
<li>An escalation in capital expenditures for new capacity so ill-conceived and poorly risk-managed that the new capacity subsequently necessitated the costly shuttering of existing capacity, including closing a manufacturing plant in Connell, WA and terminating nearly 400 employees.</li>
<li>Announcing a long-term capex target of 9%12 of revenue, substantially higher than stated maintenance capex levels of ~3% revenue, creating confusion around these elevated levels13 and with no clear roadmap for how the spend would generate sustainable and acceptable returns on capital.</li>
<li>Inexplicably permitting management to execute stock repurchases shortly before large earnings misses and dramatic declines in the Company's share price.14</li>
<li>Misaligned executive compensation targets that heavily incent growth, have no return on capital guardrails and have allowed management to earn the maximum amount (200%) of the target in FY24 on the operational performance component of the Long-Term Incentive Program's Performance Share Awards15 despite disastrous performance for investors.</li>
</ul>
</li>
<li>Questionable Use and Disclosure Practices around Aviation Assets:
<ul>
<li>Having a corporate plane to facilitate transport of employees between Boise, ID and key manufacturing locations is an understandable investment of corporate resources. However, our analysis of flight records shows that since 2019, Lamb Weston's plane has registered ~300 flights into or out of Omaha, NE – the former headquarters of Conagra and what appears to be the CEO's primary residence – and additional flights to numerous other destinations that raise questions regarding the legitimate business purpose of these flights. The Company's proxy disclosures – which show compensation of only $14,463, $13,737 and $21,349 of value for the CEO's personal use of Company aircraft in the years F2022, F2023 and F2024 and neither disclosure for any value received in earlier periods nor indication of plane usage for business purposes related to productivity and safety – seem to be at odds with our flight analysis, which raises serious questions about the use and disclosure around the Company's aviation assets.</li>
<li>In September 2023, shortly before the Company's 2023 Investor Day, when it created consternation and confusion among analysts and shareholders by announcing a new long-term capex target of 9% of revenue, Lamb Weston reserved two new tail numbers with the US Federal Aviation Administration. FAA Registry data shows these reservations were subsequently purged on October 18, 2024 – the day of JANA's 13D filing in Lamb Weston.</li>
</ul>
</li>
</ul>
This track record makes clear that the status quo is no longer tenable – and is completely unacceptable – for shareholders. JANA has a multi-decade reputation of working constructively with Boards to drive change and improve performance – in this spirit, our offer stands to work with Lamb Weston, as we and our team of highly regarded industry executives16 are prepared to join the Board immediately and help rehabilitate the Company and drive long-term value. However, if the Board is unwilling to make the significant changes needed to repair Lamb Weston, then the Company should work with its financial advisors to explore a sale and take advantage of strategic interest in the Company to achieve the highest possible risk-adjusted return for shareholders.
We look forward to the Board's prompt response.
Sincerely,
Scott Ostfeld Managing Partner &amp; Portfolio Manager

Management

JANA Partners Sends Letter To Board Of Directors Of Lamb Weston Holdings; Believes Significant Board And Leadership Change Is Necessary To Improve Performance; Absent Meaningful Board And Leadership Change, Lamb Weston Should Launch A Formal Review Of Strategic Alternatives To Maximize Value For Shareholders

JP Morgan analyst Brian Cheng downgrades Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) from Neutral to Underweight.

Downgrades

EDIT

JP Morgan Downgrades Editas Medicine to Underweight

Wedbush analyst Jay McCanless initiates coverage on Hovnanian Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOV#NYSE">HOV</a>) with a Neutral rating and announces Price Target of $155.

Initiation

Wedbush Initiates Coverage On Hovnanian Enterprises with Neutral Rating, Announces Price Target of $155

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

SMLR

Semler Scientific Purchased Additional 211 BTC For $21.5M Between Dec. 5 And Dec. 15; Now Holds 2,084 BTC

Stratasys F370&#xAE; 3D Printer and GrabCAD Print Software Enable ArcelorMittal Maizières Research's Adoption of 3D Printing for Applications Previously Unattainable with Traditional Manufacturing
ArcelorMittal, a leading steel manufacturer in Europe, has expanded its use of 3D printing by adopting the F370&#xAE; 3D printer within its research centre based in Maizières-lès-Metz, transforming the tooling and prototyping aspects of its manufacturing processes, Stratasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSYS#NASDAQ">SSYS</a>) announced today.

SSYS

ArcelorMittal And Stratasys Announce Expanded Use Of 3D Printing By Adopting The F370 3D Printer Within Its Research Centre Based In Maizières-lès-metz, Transforming The Tooling And Prototyping Aspects Of Its Manufacturing Processes

Oragenics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>), a biotechnology company advancing innovative treatments for brain-related health conditions, today announced the conversion of its remaining outstanding convertible Series A and Series B Preferred Shares into common stock. The conversion helps simplify the company's capital structure and eliminates approximately $2.35 million in liquidation preference, effectively removing a significant overhang on the company's stock.
Holders of the Company's remaining 5,417,000 Series A Preferred Shares and 4,050,000 Series B Preferred Shares exercised their right to convert their shares into a total of approximately 22,000 common shares. The Series A and B Preferred Shares, which carried no voting rights, have now been fully retired.

OGEN

Oragenics Announces Conversion Of Preferred Shares And Elimination Of Liquidation Preference; The Conversion Helps Simplify The Co's Capital Structure And Eliminates ~$2.35M In Liquidation Preference, Effectively Removing A Significant Overhang On The Company's Stock

FHTX

Foghorn Therapeutics shares rare trading lower after the company announced it will discontinue the independent development of FHD-286 in combination with Decitabine.

Northland Capital Markets analyst Mike Grondahl maintains Legacy Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LGCY#AMEX">LGCY</a>) with a Outperform and raises the price target from $8.75 to $10.

LGCY

Northland Capital Markets Maintains Outperform on Legacy Education, Raises Price Target to $10

RDZN

Roadzen shares are trading lower after the company announced a public offering of 2 million common shares priced at $1.25 per unit.

Stifel analyst Paul Matteis maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Hold and raises the price target from $490 to $494.

VRTX

Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $494

U.S. stock futures were slightly higher this morning, with the Nasdaq futures gaining around 0.2% points on Monday.
Shares of Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) fell sharply in today's pre-market trading following reports suggesting the company tapped Evercore to raise capital and is considering raising<a href="https://www.benzinga.com/quote/SMCI/news"> equity and debt</a>.
Super Micro Computer shares dipped 12.5% to $31.85 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Tile Shop Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTSH#NASDAQ">TTSH</a>) shares declined 11.5% to $6.10 in pre-market trading.</li>
<li>KalVista Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) fell 7.9% to $8.00 in pre-market trading.</li>
<li>Kearny Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNY#NASDAQ">KRNY</a>) shares declined 6.5% to $7.51 in pre-market trading.</li>
<li>Innovex International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVX#NASDAQ">INVX</a>) fell 5.8% to $12.52 in pre-market trading.</li>
<li>MAC Copper Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTAL#NYSE">MTAL</a>) fell 5.7% to $11.50 in pre-market trading after declining 4% on Friday.</li>
<li>Innventure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INV#NASDAQ">INV</a>) fell 5.2% to $11.90 in pre-market trading.</li>
<li>Viemed Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) fell 5% to $8.30 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42482639/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 6% Dividend Yields</a></li>
</ul>

INVX

KALV

KRNY

MTAL

TTSH

Super Micro Computer And Other Big Stocks Moving Lower In Monday's Pre-Market Session

FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments for FSAD; Daré's Sildenafil Cream has the potential to receive the first FDA approval for FSAD.
Market research estimates approximately 10 million women in the U.S. are distressed from experiencing symptoms associated with FSAD and are actively seeking solutions to improve their condition.
SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Daré&nbsp;Bioscience, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>), a leader in innovation for the health and wellbeing of women, and its collaborator&nbsp;Strategic Science &amp; Technologies, LLC&nbsp;(SST), a&nbsp;Cambridge, MA&nbsp;based novel topical drug delivery company, today announced plans for a Phase 3 study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for female sexual arousal disorder (FSAD), reflecting U.S. Food and Drug Administration (FDA) feedback for safety and efficacy evaluations to support the indication of treatment of FSAD in premenopausal women.

Biotech

DARE

Daré Bioscience Announces Phase 3 Plans For Sildenafil Cream, 3.6%, In The Treatment Of Female Sexual Arousal Disorder; Daré's Sildenafil Cream Has The Potential To Receive The First FDA Approval For FSAD

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst Eric Sheridan initiated coverage on Grindr Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) with a Buy rating and announced a price target of $20. Grindr shares closed at $15.74 on Friday. See how other analysts view this stock.</li>
<li>JMP Securities analyst Constantine Davides initiated coverage on Addus HomeCare Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Market Outperform rating and announced a price target of $150. Addus HomeCare shares closed at $125.00 on Friday. <a href="https://www.benzinga.com/quote/ADUS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Matthew Caufield initiated coverage on Zenas BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) with a Buy rating and announced a price target of $30. Zenas BioPharma shares closed at $8.92 on Friday. <a href="https://www.benzinga.com/quote/ZBIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Constantine Davides initiated coverage on U.S. Physical Therapy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Market Outperform rating and announced a price target of $113. US Physical Therapy shares closed at $93.46 on Friday. See how other analysts view this stock.</li>
<li>Jones Trading analyst Justin Walsh initiated coverage on Alto Neuroscience, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) with a Buy rating and announced a price target of $18. Alto Neuroscience shares closed at $3.83 on Friday. <a href="https://www.benzinga.com/quote/ANRO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ADUS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="628" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-1024x628.png" alt="" class="wp-image-693734" style="width:595px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-1024x628.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-768x471.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 6% Dividend Yields

ADUS

ANRO

GRND

USPH

ZBIO

This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

JP Morgan analyst Anthony Paolone maintains Cushman &amp; Wakefield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWK#NYSE">CWK</a>) with a Neutral and raises the price target from $14 to $17.

JP Morgan Maintains Neutral on Cushman & Wakefield, Raises Price Target to $17

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) from Overweight to Overweight.

ARCT

Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeuticsto Overweight

Biggest stock movers Tuesday: T, X, ZS, SMCI, and more

Credo Technology Q2: Infection Point Has Arrived

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: The Delaware Court of Chancery y...

AT&T announces long-term targets, BlackRock acquires HPS: Morning Buzz

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Zscaler (ZS – Research Report), Credo Technology G...

Analysts Offer Insights on Technology Companies: Zscaler (ZS), Credo Technology Group Holding Ltd (CRDO) and Bill.com Holdings (BILL)

Which subsectors to own and which to avoid – Wolfe Research

Barclays Sticks to Their Buy Rating for Credo Technology Group Holding Ltd (CRDO)

Dell, Nvidia, others may benefit from modular data centers for AI: Mizuho

Semiconductor Recovery Expands Beyond AI To Automotive, PCs

Credo's Huge AI Growth Runway Is Confirmed By An Industry Bellwether

Nvidia, Broadcom, Marvell among BofA's top chip stocks for 2025

AAPL

ALAB

AMZN

AVGO

BBAI

BILI

BILL

BRCC

BYDDF

BYDDY

CART

CDNS

COHR

DBAW

DELL

DFAX

ESPO

FTXG

FTXL

GLBE

GOOGL

IBUY

INDI

INTC

JANX

KBWB

LRCX

MAGS

MATV

MCHP

MSFT

MTSI

NISTF

NLSP

NPSCY

NVDA

ONLN

PLTR

PRCH

PRFX

QUAL

RCAT

REPYY

RGTI

SCHG

SDVY

SMOT

SOCL

SOXQ

SOXX

SPYG

SPYV

STLA

SUPV

TMDX

TRAW

TROX

TSLA

TZOO

UPST

WEST

Press Releases

Credo Introduces 800G HiWire ZeroFlap AECs to Support AI Backend Networks

Credo to Showcase Datacenter AI, Compute and CXL with XConn PCIe and CXL Switches at OCP Global Summit 2024

Credo Announces PCI Express 6 /7, Compute Express Link CXL 3.x Retimers, and AEC PCI Express Product Line at OCP Summit 2024

Credo and Net One Systems Join Forces to Bring Active Electrical Cables to the Japanese Market

Credo Schedules Second Quarter Fiscal Year 2025 Financial Results Conference Call

Credo Completes First GHG Emissions Calculation, Strengthens Commitment to Environmental Sustainability

Credo Releases 2024 Environmental, Social, and Governance (ESG) Report

Credo to Present at Barclays 22nd Annual Global Technology Conference

Credo Reports Second Quarter of Fiscal Year 2025 Financial Results

Demand For Helium is Becoming an Extremely High-Value Commodity and Billion Dollar Industry

NEHC

NEHCW

PSRHF

ROCL

TSXV:PLSR

Analog Devices

Astera Labs

Advanced Micro Devices, Inc. - Common Stock

Advanced Micro Devices

Arm Holdings plc - American Depositary Shares

ARM Holdings

ASE Technology Holding Co., Ltd. American Depositary Shares (each representing Two Common Shares)

ASE Tech Holding Co

Broadcom

First Solar

Comments

Credo Technology Group

매도 수량

Credo Technology Group (NASDAQ:CRDO) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌